SCHEMBL4125610

SCHEMBL4125610

Cc1cc(/C=C2/SC(Nc3nc(CC(=O)O)cs3)=NC2=O)nn1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.46
GAA P10253 5/20 0.46
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
KDM4E B2RXH2 2/20 0.42
RECQL P46063 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
NSD2 O96028 1/20 0.42
POLB P06746 1/20 0.42
APEX1 P27695 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
ALDH1A1 P00352 6/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4125618 1.00 MAPT (0.46) MAPTGAAMEN1KMT2AKDM4E
SCHEMBL4143530 0.82 MAPT (0.44) MAPTMEN1KMT2AKDM4ERECQL
SCHEMBL4143522 0.82 MAPT (0.44) MAPTMEN1KMT2AKDM4ERECQL
SCHEMBL4128240 0.77 GAA (0.45) MAPTGAAALDH1A1NPC1RAB9A
SCHEMBL4128243 0.77 GAA (0.45) MAPTGAAALDH1A1NPC1RAB9A
SCHEMBL4127746 0.72 PTP4A3 (0.48) MAPTGAAMEN1KMT2AKDM4E
SCHEMBL4127740 0.72 PTP4A3 (0.48) MAPTGAAMEN1KMT2AKDM4E
SCHEMBL4121784 0.70 NSD2 (0.37) MAPTGAAMEN1KMT2AKDM4E
SCHEMBL4121787 0.70 NSD2 (0.37) MAPTGAAMEN1KMT2AKDM4E
SCHEMBL4125617 0.66 GAA (0.46) MAPTGAAKDM4EPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ MAPT 3532/4885GAA 387/4885MEN1 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.